Wells Fargo & Company MN Has $903,000 Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Wells Fargo & Company MN lowered its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 22.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 98,367 shares of the medical technology company's stock after selling 27,759 shares during the period. Wells Fargo & Company MN owned about 0.07% of Alphatec worth $903,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC raised its stake in Alphatec by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 2,387,162 shares of the medical technology company's stock valued at $21,919,000 after purchasing an additional 24,283 shares during the period. CIBC Private Wealth Group LLC raised its position in Alphatec by 19.1% during the fourth quarter. CIBC Private Wealth Group LLC now owns 17,154 shares of the medical technology company's stock valued at $166,000 after buying an additional 2,750 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Alphatec by 9.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,942 shares of the medical technology company's stock worth $365,000 after acquiring an additional 3,336 shares in the last quarter. Zions Bancorporation N.A. lifted its stake in Alphatec by 16.6% in the 4th quarter. Zions Bancorporation N.A. now owns 201,882 shares of the medical technology company's stock worth $1,853,000 after acquiring an additional 28,702 shares in the last quarter. Finally, Emerald Advisers LLC boosted its position in Alphatec by 112.4% during the 4th quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock worth $13,366,000 after acquiring an additional 770,586 shares during the period. 66.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and issued a $16.00 price target on shares of Alphatec in a research report on Friday. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Piper Sandler reissued an "overweight" rating and set a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research note on Friday. Barclays upped their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $17.89.

Insider Transactions at Alphatec

In related news, COO Scott Lish sold 12,000 shares of the business's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $12.12, for a total transaction of $145,440.00. Following the completion of the transaction, the chief operating officer now owns 826,251 shares of the company's stock, valued at approximately $10,014,162.12. The trade was a 1.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 43,459 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $11.95, for a total value of $519,335.05. Following the sale, the chief executive officer now owns 6,065,772 shares of the company's stock, valued at approximately $72,485,975.40. The trade was a 0.71 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 197,857 shares of company stock worth $2,251,122. 22.80% of the stock is owned by insiders.

Alphatec Stock Up 2.1 %

Alphatec stock traded up $0.25 during mid-day trading on Tuesday, hitting $12.23. 2,216,966 shares of the company's stock were exchanged, compared to its average volume of 2,080,578. Alphatec Holdings, Inc. has a 1-year low of $4.88 and a 1-year high of $13.63. The stock has a 50 day moving average of $10.48 and a two-hundred day moving average of $9.98. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The stock has a market cap of $1.79 billion, a P/E ratio of -9.55 and a beta of 1.06.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The company had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same period in the prior year, the company posted ($0.34) EPS. The business's revenue was up 22.2% on a year-over-year basis. As a group, analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.